You are here

Preclinical Development of Novel MEK1/2 Inhibitors to Treat Inherited Cardiomyopa

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41TR001008-01A1
Agency Tracking Number: R41TR001008
Amount: $99,976.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCATS
Solicitation Number: PA12-089
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
150 MUNSON ST, 25 SCIENCE PARK AT YALE
NEW HAVEN, CT 06511-
United States
DUNS: 859393352
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 UDAY KHIRE
 (860) 679-6893
 uday.khire@cheminpharma.com
Business Contact
 UDAY KHIRE
Phone: (860) 679-6893
Email: uday.khire@cheminpharma.com
Research Institution
 COLUMBIA UNIVERSITY
 
COLUMBIA UNIVERSITY 1700 BROADWAY
NEW YORK, NY 10017-
United States

 () -
 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant): Cardiomyopathy is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, usually with inappropriate ventricular hypertrophy or dilatation. There are various causes of cardiomyopathy, many of which are genetic. Dilated cardiomyopathy, the most common form, is characterized by an increase in both myocardial mass and volume. There is no definitive, curative treatment. Research performed at Columbia University has revealed that abnormal activation of the extracellular signal-regulated 1/2 (ERK1/2) branch of the mitogen-activated protein kinase (MAPK) cascade occurs in hearts of Lmna H222P knock-in mice, a model of inherited dilated cardiomyopathy caused by mutation in the lamin A/C gene, which is responsible for about 8% of inherited dilated cardiomyopathies in humans. The research at Columbia has further shown that inhibitors of MAPK/ERK kinase1/2 (MEK1/2), the enzyme that activates ERK1/2, prevent ventricular dilatation, improvecardiac contractility and delay the development of fibrosis in Lmna H222P mice. The goal of the present Small Business Technology Transfer grant proposal is to develop and commercialize this discovery made at Columbia into a treatment for human patients with cardiomyopathy caused by lamin A/C gene mutation. The project is a collaborative effort between Cheminpharma LLC, which has invented and synthesized a proprietary and potent MEK1/2 inhibitor, and the scientists at Columbia who made the initial discoveries. Aim 1 is to test Cheminpharma's novel MEK1/2 inhibitor, CIP-137401, in the Lmna H222P mouse model of dilated cardiomyopathy. Aim 2 is to carry out a synthetic route of CIP-137401 to allow for the efficient synthesis of material to support IND enablingstudies. This proposal will identif a proprietary MEK1/2 inhibitor with in vivo activity that could be suitable for clinical developmen to treat patients with inherited dilated cardiomyopathy. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Cardiomyopathy is a life-threatening disease that leads to heart failure and death for which there is currently no curative treatment. This project is designed to develop and commercialize a novel drug known as a MEK1/2 inhibitor to treat cardiomyopathy, initially focusing on a specific inherited type.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government